IIa in Medical Technology

BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis

TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This dou...

Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia

SOUTHAMPTON, England, June 29 /PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for no...

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial

Results show improved insulin sensitivity and lower glucose levels without the side effects of current therapies KALAMAZOO, Mich., May 14 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC) announced today that its lead compound, MSDC-0160, can improve insulin sensitivity and lo...

TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee

ROCKVILLE, Md., March 2 /PRNewswire/ -- TissueGene, Inc. announced today that its South Korean licensing partner Kolon Life Science, Inc. (KLS) has received regulatory allowance from the Korea Food and Drug Administration (KFDA) to initiate a Phase IIa clinical trial of TissueGene-C (TG-C) in pati...

Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced the initiation of a proof-of-concept clinical trial of SLC022 in patients with post-herpetic neuralgia (PHN). PHN, a painful co...

Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate

Favorable immunogenicity results for seasonal vaccine program follows positive results from its pandemic influenza vaccine Phase IIa trial in July 2008; plans to initiate a study of the seasonal vaccine in the elderly in 2009 ROCKVILLE, Md., Dec. 11 /PRNewswire-FirstCall/ -- Novavax, Inc...

Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program

Reduction in Tachycardia and Blood Acetaldehyde Levels in Subset of Subjects with Inborn Error of Alcohol Metabolism NOVATO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced positive results in its ...

Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System

DURHAM, N.C., Oct. 10 /PRNewswire/ -- Regado Biosciences, Inc., announced today the Company has completed enrollment in the Phase IIa clinical study of its REG1 Anticoagulation System in patients undergoing elective percutaneous coronary intervention (PCI). REG1 is a two-component system compo...

Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients

SAN FRANCISCO, July 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced that it has dosed the first acute setting heart failure patient in its Phase IIa, multi-center, open-label, ascending dose clinical study of the company's lead product candidate, CD-NP, a...

Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference

BALTIMORE, May 21 /PRNewswire/ -- Alba Therapeutics Corporation announced today that data from its Phase IIa clinical trial were presented in the Clinical Advances in Celiac Disease session at the Digestive Disease Week (DDW) meeting in San Diego, California. Results of the randomized, double-...

Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)

Patient Dosing Underway in Company's First Clinical Program NOVATO, Calif., April 21 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. ("Bennu...

Inverseon Announces Positive Phase IIa Asthma Study

SAN FRANCISCO, Jan. 29 /PRNewswire/ -- Inverseon, Inc. ( http://www.inverseon.com ) announces the publication of a positive phase IIa clinical trial in asthma. In the article by Hanania et al., in Pulmonary Pharmacology & Therapeutics, vol. 21, (2008), pp. 134-141, entitled, "The safety and ...

Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, Jan. 9 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN ) today announced positive topline results from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. With these results, t...

Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF

-Initial 10 mcg/kg MAXY-G34 Cohort Met Key Safety Criterion of Duration of Neutropenia- -No Serious Adverse Events or Immunogenicity to Date- REDWOOD CITY, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY ) today announced positive progr...

DURECT Announces Positive ELADUR(TM) Phase IIa Study Results

CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX ) announced today positive results from a Phase IIa clinical trial for ELADUR(TM), DURECT's proprietary investigational transdermal pain patch. In this study of patients suffering from post-herpetic neuralgi...

VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor

BASKING RIDGE, N.J., Nov. 26 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals (OTC Bulletin Board: VQPH) today announced the initiation of a Phase IIa study of Lenocta(TM) (sodium stibogluconate), a novel protein tyrosine phosphatase inhibitor, in combination with interferon alpha, an immune...

Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System

DURHAM, N.C., Nov. 1 /PRNewswire/ -- Regado Biosciences today announced the enrollment of the first patient in a multi-center, open-label, randomized Phase IIa clinical study, named REVERSAL-PCI, of its REG1 Anticoagulation System. The patient was enrolled at Black Hills Cardiology in Rapid Ci...

Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients

SCHLIEREN (Zurich), Switzerland, March 13, 2007 - Cytos Biotechnology AG (SWX:CYTN) reported today positive results from a phase IIa study with CYT003-QbG10, an immunotherapeutic product candidate for the treatment of allergic diseases. The study included 40 patients suffering from mild to moderat...

AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure

Results expand potential application of key product in AM-Pharma's pipeline BUNNIK, The Netherlands, 14 March, 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced positive results in patients with Acute ...

Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation

Initial Analysis Shows Statistically Significant Changes in Agitation Levels With 10 mg AZ-004 PALO ALTO, Calif., March 26, 2007 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. today announced positive initial results from its Phase IIa clinical trial of AZ-004 (Staccato(R) loxapine) in sch...

Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine

GENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with migraine. The study achieved its primary objective, the absence of pain at 2 hours after dosing, with statis...

Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy

Cytos Biotechnology reports positive results from placebo controlled phase IIa study in patients suffering from house dust mite allergy SCHLIEREN (Zurich), Switzerland, May 15, 2007 - Cytos Biotechnology AG (SWX:CYTN) reported today positive results from a multi-centre and placebo-controlled pha...

Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease Presented at International Congress of Parkinson's Disease and Movement Disorders

Faust's lead molecule, FP0011, exhibited a differentiated combination of therapeutic effects and good tolerance in mid- to late-stage patients STRASBOURG, France, June 6, 2007 - Faust Pharmaceuticals S.A., a clinical stage product company specializing in the discovery and development of drugs for ...

Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis

RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS WIRE)--Jun 26, 2007 - Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal and metabolic diseases, today announced positive results for its novel ghrelin agonist, T...

Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Next Generation Renin Inhibitor to Continue Phase II Profiling in Diabetic Patients BASEL/Switzerland and BRIDGEWATER NJ/USA, 28 June 2007-Speedel (SWX: SPPN) today announced that it has reached another significant milestone in the development of its family of renin inhibitors with the succes...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos Biotechnology AG (SWX:CYTN) announced today results from a phase IIa study with CYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is an immunotherapeutic product candidate currently in development for the treatment of allergic diseases. The presen...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa Clinical Trial Results First clinical Results Confirm Potential New Application of Key Product in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to trea...

Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

...enrollment has been completed in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase iia randomized, placebo-controlled study is evaluating a VLP vaccine against the H3N2, H1N1, and B influenza strains that circulated in the 2008-2009 infl...

PRA International: Participating Sponsor for Exploratory Clinical Development World in London

...elopment model that brings the center to the patients in Central/Eastern Europe, PRA's EDS group provides comprehensive services for Phase I and Phase iia studies. PRA's integrated data support, in-house pharmacy and expedited regulatory approval timelines in The Netherlands enable PRA to reduce timelin...

Clinical Update - Debio 025 in Hepatitis C

... field of oncology, presented results from a phase iia study with Debio 025, a selective cyclophilin (Cyp...showed potent antiviral activity. The phase iia study investigated the efficacy and safety of Debi...e step closer to our goal." About the phase iia triple therapy study Debiopharm investigate...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

...rated, with no drug related serious adverse events. Pharmacokinetic and pharmacodynamic modeling from this study was used to design the ongoing Phase iia dose-finding study of SCH 900518 with ritonavir in combination with PEGINTRON and REBETOL. This study, known as NEXT-1, explores SCH 900518 in 200 mg...

Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth

...ional Review Board (IRB) and performed in accordance with Good Clinical Practices. Subjects were required to have a Norwood Hamilton classification of iia to V based on the Male Classification System of Hair Loss, and have Fitzpatrick Skin Type Scale I through IV. Of the patients who completed the ...

Vantia Therapeutics' Pipeline Continues to Mature

... /PRNewswire/ -- - VA106483 Completes Phase iia Trial and VA111913 Completes Phase I Dosing ... Following the completion of the 27-patient Phase iia trial of VA106483, a vasopressin agonist, results ... is also expected to report data in H1 2009. Phase iia trials are expected to start in the second half of...

Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma

...erleukin-13 (IL-13), critical in the progression of the disease. Our Phase iia data suggest that targeted delivery to the lung is superior to systemic adm... a dry powder formulation and follows positive clinical data from two Phase iia studies in which Aerovant demonstrated significant benefit in asthmatics wh...

ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease

... progressing well. Patient enrolment for the Phase iia trial assessing EHT 0202 in patients with Alzheime...al companies that are looking forward to the Phase iia results." The trial is conducted under the ...ow the evolution of the disease." The Phase iia trial is a multicenter, randomized, double-blind, ...

Clinical Update - Debio 025 in Hepatitis C

...rapy for 15 days induced a strong anti-HCV effect (3.6 log10 reduction) in HIV-1/HCV co-infected patients. (Hepatology, 47:817-26). Results of a phase iia study with Debio 025 indicate that Debio 025 shows an important additive anti-HCV effect (4.6 log10 reduction) when co-administered with peg-IFNalpha2...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

...n-class potential. The compound, known as SCH 900518 is currently in Phase iia clinical development. The update was presented today as part of the compan...ping SCH 900518 ("518"), a next-generation HCV protease inhibitor. A Phase iia study with 518, known as the NEXT-1 study, is currently ongoing. The compa...

Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million

...l trial of RAD1901, a novel SERM (selective estrogen receptor modulator) for the treatment of hot flashes, on which Radius expects to commence a Phase iia study in the first quarter of 2009. In addition, the company recently announced selection of the first preclinical candidate from its SARM (selective ...

Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008

...ate-breaker poster on the proof-of-principle phase iia trial, OPERA-1 (TMC435-C201), at the American Asso...th shorter treatment duration.(2,3) TMC435 Phase iia Study Results In interim findings from the first...ding HCV, HIV and tuberculosis." About the Phase iia Study Investigators in five European countries a...

Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting

...cal studies this week at the American College of Gastroenterology (ACG) 2008 Annual Scientific Meeting. Data from study CLIN 1001-004, the first Phase iia trial conducted in celiac disease and the first to assess the prevention of immunologic changes in celiac disease, showed that larazotide acetate (AT-...